Welcome to our dedicated page for Nuvalent news (Ticker: NUVL), a resource for investors and traders seeking the latest updates and insights on Nuvalent stock.
Nuvalent, Inc. develops precisely targeted small-molecule therapies for clinically proven kinase targets in cancer. Its news centers on investigational programs including zidesamtinib for ROS1-positive NSCLC, neladalkib for ALK-positive NSCLC, and HER2-altered NSCLC research, with updates on clinical data from ARROS-1 and ALKOVE-1, FDA submission activity, companion-diagnostic collaborations, and discovery-stage programs.
Company updates also cover quarterly financial results, research and development spending, cash resources, commercial-readiness activities for potential oncology launches, medical-meeting presentations, and leadership or governance developments tied to its clinical-stage biopharmaceutical model.
Nuvalent, a biopharmaceutical firm, has priced its initial public offering (IPO) at $17.00 per share, expecting gross proceeds of approximately $165.75 million. The IPO includes 9,750,000 shares, divided into 9,150,000 Class A and 600,000 Class B shares, with trading on Nasdaq set to begin on July 29, 2021. The offering is anticipated to close by August 2, 2021, subject to typical closing conditions. J.P. Morgan, Cowen, and Piper Sandler are the joint book-running managers.